SCHEMBL6725484

SCHEMBL6725484

Cc1ncccc1-c1noc(C(F)F)c1-c1ccc(S(C)(=O)=O)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.40
PTGS1 P23219 2/20 0.40
SYK P43405 1/20 0.39
ALOX5AP P20292 5/20 0.36
FEN1 P39748 5/20 0.36
PIK3CD O00329 2/20 0.36
PIK3CA P42336 2/20 0.36
PIK3CB P42338 2/20 0.36
PIK3CG P48736 2/20 0.36
GRM4 Q14833 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
CSNK1D P48730 2/20 0.34
MAPK14 Q16539 2/20 0.34
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
GPR119 Q8TDV5 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723607 0.91 PTGS2 (0.41) PTGS2PTGS1ALOX5APFEN1PDE3B
SCHEMBL6733086 0.87 PTGS2 (0.39) PTGS2PTGS1ALOX5APFEN1PDE3B
SCHEMBL6723102 0.87 PTGS2 (0.46) PTGS2PTGS1SYKPIK3CDPIK3CA
SCHEMBL6723710 0.84 PTGS2 (0.45) PTGS2PTGS1CSNK1DMAPK14
SCHEMBL6722731 0.84 PTGS2 (0.42) PTGS2PTGS1PIK3CDPIK3CAPIK3CB
SCHEMBL6725599 0.83 PTGS2 (0.41) PTGS2PTGS1SYKALOX5APFEN1
SCHEMBL6722998 0.83 PTGS2 (0.38) PTGS2PTGS1SYKCSNK1DMAPK14
SCHEMBL6721594 0.83 PTGS2 (0.48) PTGS2PTGS1SYKALOX5APFEN1
SCHEMBL6722938 0.83 PTGS2 (0.39) PTGS2PTGS1PIK3CDPIK3CAPIK3CB
SCHEMBL6722025 0.83 PTGS2 (0.39) PTGS2PTGS1PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885SYK 336/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885SYK 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.